In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Kessler opposes "direct additives" Delaney reform -- House Commerce hearing.

This article was originally published in The Rose Sheet

Executive Summary

FDA's KESSLER OPPOSES DELANEY CLAUSE REFORM FOR "DIRECT ADDITIVES" at a House Commerce/Health and Environment subcommittee hearing on FDA reform on May 1. Referring to the provision in HR 3200 that replaces the Delaney clause's "zero cancer risk" standard for food and color additives, animal drugs and pesticides with a negligible or de minimus risk standard, Commissioner David Kessler, MD, asserted that since "HR 3200's safety standard...would result in the intentional addition to the diets of American consumers carcinogenic food and color additives" that have not previously been permitted, "I am not in favor of changing Delaney when it comes to direct intentional food additives." Sponsored by Rep. Scott Klug (R-Wis.), the FDA reform bill addressing foods was introduced March 29 ("The Rose Sheet" April 1, p. 1).

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel